ZHANG Hang , WANG Huajun , SHI Fengwu , LIU Su , MA Qianli , AN Jinghui
  • Department of Cardiac surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, P. R. China;
AN Jinghui, Email: Anjinghui2009@126.com
Severe aortic stenosis; transcatheter aortic valve replacement; Venus A-Plus; Venus A
10.7507/1007-4848.202402037
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective  To evaluate the short-term efficacy of transcatheter aortic valve replacement (TAVR) using Venus A-Plus valve delivery system in patients with severe aortic stenosis. Methods  The clinical data of patients undergoing TAVR in our hospital from August 2018 to March 2022 were collected and divided into a Venus A-PLUS and a Venus A group according to the type of valve delivery system used. The perioperative data of the two groups were compared. Results A total of 121 patients were included, including 70 patients in the Venus A-Plus group (45 males and 25 females with a mean age of 67.81±6.62 years), and 51 patients in the Venus A group (33 males and 18 females with a mean age of 68.25±7.01 years). All patients underwent TAVR, and the postoperative hemodynamic features (left ventricular ejection fraction, mean cross-valve pressure difference, peak flow rate) were significantly improved (P<0.05). There was no statistical difference in surgical success rate, all-cause mortality, conversion to thorax opening, midvalve placement, moderate or above perivalvular regurgitation, new left bundle branch block or new right bundle branch block between the two groups (P>0.05). Conclusion  TAVR with Venus A-Plus valve delivery system in patients with severe aortic stenosis is satisfactory, safe and reliable.